Antinociceptive profile of sulfated CCK-8

Barbaz, B. S.; Autry, W.L.; Ambrose, Frances G.; Hall, Nancy; Liebman, Jeffrey M.

doi:10.1016/0028-3908(86)90005-5

Cited by 46 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar effect has previously been shown with other cholecystokinin peptides (Jura & Zetler 1981;Barbaz et al 1986;Slaninova et al 1991;. The obtained results are also in agreement with our previous study that caerulein induces antinociception in hot-plate tests (Zarrindast et al 1997), although other reports have indicated that cholecystokinin does not alter pain response in the tail-flick test (Moran et al 1986;Dourish et al 1988;O'Neill 1989).…”

Section: Discussionsupporting

confidence: 81%

Role of Cholecystokinin Receptors in Induction of Antinociception in Hot‐Plate Test

Rezayat

Rahnavard

Zarrindast³

2000

Pharmacology & Toxicology

View full text Add to dashboard Cite

In the present study, the antinociceptive effect of cholecystokinin receptor agonists in the hot-plate test in mice has been evaluated. Subcutaneous administration of cholecystokinin octapeptide (cholecystokinin-8; 0.001, 0.005, 0.01, 0.05, and 0.1 mg/kg), unsulfated cholecystokinin octapeptide (cholecystokinin-8U; 0.1 mg/kg) or caerulein (0.25 mg/kg) produced antinociception. Administration of the cholecystokinin tetrapeptide (cholecystokinin-4; 0.25, 0.5 and 1.0 mg/ kg) had no effect in the hot-plate test. Subcutaneous injection of the selective cholecystokinin receptor antagonists, MK-329 (0.125, 0.25 and 0.5 mg/kg) or L-365,260 (0.125, 0.25 and 0.5 mg/kg), produced no antinociceptive response. When the animals were pretreated with the cholecystokinin receptor antagonists or naloxone (0.5 and 1 mg/kg), a significant decrease in the antinociceptive response induced by cholecystokinin-8 and caerulein was obtained. The results indicate that single administration of cholecystokinin receptor agonists could produce an antinociceptive effect which is probably mediated via cholecystokinin receptors. With respect to the results obtained from morphine and naloxone administration, it is concluded that there may be an interaction between cholecystokinin and opiate mechanisms.The peptide, cholecystokinin, is found in the mammalian nervous system (Vanderhaeghen et al. 1975;Rehfeld 1978;Faris et al. 1983). Caerulein is closely related to the naturally occurring cholecystokinin-8 (Rehfeld & Hansen 1984;Baber et al. 1989). Cholecystokinin-8 and related peptides produce several neural-mediated effects after both peripheral and central administration (Zelter 1982;Baber et al. 1989). Cholecystokinin-like immunoreactivity has been described in areas of the spinal cord and brain which are believed to play a role in nociception. Sulfated cholecystokinin-8 and the small amounts of cholecystokinin-4 are thought to be present in many regions of the midbrain including the periaqueductal gray and substantia nigra, which are important areas in pain modulation (Baber et al. 1989). Exogenously applied cholecystokinin-8 and related peptides have produced different results on pain modulation in rodents (Wiesenfeld-Hallin et al. 1990). Cholecystokinin-8 has been found to reduce the analgesic effect of the morphine and b-endorphin (Itoh et al. 1982). Our previous results also show that pretreatment of mice with cholecystokinin receptor agonist (Cesselin 1995) decreased or increased the morphine-induced antinociception depending on pretreatment time . There is also evidence indicating that the cholecystokinin mechanism may play an important role in pain transmission by modulating CNS opiate mechanisms (Jurna & Zetler 1981;Suh et al. 1992). It has also been suggested that there may be multiple 1986). The highly selective and potent cholecystokinin-A receptor antagonists, MK-329 and L-365,260 are now available, which opens the possibility to evaluate the role of cholecystokinin receptor types in mechanism of pain system (Wiesenfeld-Hal...

show abstract

Section: Discussionsupporting

confidence: 81%

Role of Cholecystokinin Receptors in Induction of Antinociception in Hot‐Plate Test

Rezayat

Rahnavard

Zarrindast³

2000

Pharmacology & Toxicology

View full text Add to dashboard Cite

show abstract

“…It has been shown that stimulation of the cholecystokinin-A receptor induces analgesia, which can be reversed by naloxone (Derrien et al 1993). Caerulein and cholecystokinin-8 has been also shown to induce antinociception in the hot-plate test (Barbaz et al 1986;Hill et al 1987). The hot-plate test involves a higher center in pain assessment (Baber et al 1989;Hill et al 1987), indicating involvement of this center in the present response of caerulein in neuropathic pain.…”

Section: Discussionmentioning

confidence: 99%

“…Cholecystokinin fulfills many of the criteria for a neurotransmitter and may have a role in various CNS functions (Woodruff & Hughes 1991;Zarrindast et al 1997). Cholecystokinin may influence opiate-induced antinociception (Itoh et al 1982;Zetler 1982;Faris et al 1983;Barbaz et al 1986;Suh et al 1992). The overlapping distribution of endogenous opioid and cholecystokinin peptides and of their receptors in the CNS has led to a large number of studies aimed at clarifying the functional relationship between opioid and cholecystokinin systems (Dauge et al 1995).…”

mentioning

confidence: 99%

Antinociceptive Effect of Intracerebroventricular Administration of Cholecystokinin Receptor Agonist and Antagonist in Nerve‐Ligated Mice

Zarrindast¹,

Samiee

Rezayat

2000

Pharmacology & Toxicology

View full text Add to dashboard Cite

In the present study we investigated the effects of intracerebroventricular injection of caerulein, the cholecystokinin receptor agonist and proglumide, the receptor antagonist on morphine response in the sciatic nerve ligation in mice. Subcutaneous administration of morphine induced antinociception in the both intact and ligated mice, however, the response of the opioid was lower in the ligated mice as compared with the intact animals. Caerulein induced antinociception in the non-ligated but not in the nerve-ligated animals. Combination of caerulein with morphine elicited higher response in ligated animals, however, the response induced in ligated animals was much more prominent. Proglumide alone did not elicit any response in both animal groups. The antagonist decreased the response of caerulein in the nonligated mice. Low doses of proglumide in the combination with caerulein induced antinociception in the ligated mice. We conclude that cholecystokinin receptor mechanism(s) may alter morphine resistance induced by nerve ligation.Cholecystokinin is a neuropeptide that mainly occurs in the central nervous system (CNS), primarily as the sulphated octapeptide, cholecystokinin-8S. Cholecystokinin interacts with two distinct types of receptors, namely cholecystokinin-A (alimentary) and cholecystokinin-B (brain) (Moran et al. 1986). Both receptors are present in the brain. Cholecystokinin fulfills many of the criteria for a neurotransmitter and may have a role in various CNS functions (Woodruff & Hughes 1991;Zarrindast et al. 1997). Cholecystokinin may influence opiate-induced antinociception (Itoh et al. 1982;Zetler 1982;Faris et al. 1983;Barbaz et al. 1986;Suh et al. 1992). The overlapping distribution of endogenous opioid and cholecystokinin peptides and of their receptors in the CNS has led to a large number of studies aimed at clarifying the functional relationship between opioid and cholecystokinin systems (Dauge et al. 1995).Neuropathic pains arising from peripheral nerve injury can result in increased sensitivity to both noxious (hyperalgesia) and non-noxious stimuli (allodynia) and are accompanied by a number of neuroplastic alterations at the level of the spinal cord including up-regulation of neurotransmitters such as dynorphin, cholecystokinin and neuropeptide Y (Nichols et al. 1997), and lead to abnormal pain states referred to as neuropathic pain. The lack of efficacy of opioids against neuropathic pain, produced by diseases or damage to the nervous system, not only reduces their effectiveness but also complicates the managements of patients with persistent pain (Inturrisi 1990;Foley 1991 thy produced by persistent moderate constriction of the common sciatic nerve, has been studied extensively (Mao et al. 1995;Ossipov et al. 1995). In the present study we studied the involvement of cholecystokinin receptor mechanism(s) in neuropathic pain, and the effects of caerulein and proglumide on the antinociceptive response of morphine in sciatic nerve-ligated mice. Materials and MethodsAnimals. Male NM...

show abstract

“…The first sulfakinin gene identified, D. melanogaster sulfakinin (Dsk), encodes two structurally-related peptides, drosulfakinin I (DSK I; FDDYGHMRFNH 2 ) and drosulfakinin II (DSK II; GGDDQFDDYGHMRFNH 2 ) [34]. Like their vertebrate homologues, the cholecystokinin (CCK) peptides, naturally-occurring sulfakinins contain a sulfated or nonsulfated tyrosyl residue [1, 3, 5, 17, 23, 31, 32, 35, 36]. The sulfated and nonsulfated drosulfakinin I and drosulfakinin II peptides are designated sDSK I and nsDSK I and sDSK II and nsDSK II, respectively.…”

Section: Introductionmentioning

confidence: 99%

The different effects of structurally related sulfakinins on Drosophila melanogaster odor preference and locomotion suggest involvement of distinct mechanisms

et al. 2008

View full text Add to dashboard Cite

Sulfakinins are myoactive peptides and antifeedant factors. Naturally-occurring drosulfakinin I (DSK I; FDDYGHMRFNH2) and drosulfakinin II (DSK II; GGDDQFDDYGHMRFNH2) contain sulfated or nonsulfated tyrosine. We discovered sDSK II and nsDSK II influenced D. melanogaster larval odor preference. However, sDSK I, nsDSK I, MRFNH2, and saline did not influence odor preference. We discovered sDSK I and nsDSK I influenced larval locomotion. However, sDSK II, nsDSK II, MRFNH2, and saline did not influence locomotion. Our novel data suggest distinct mechanisms underlie the effects of DSK I and DSK II peptides on odor preference and locomotion, parameters important to many facets of animal survival.

show abstract

Antinociceptive profile of sulfated CCK-8

Cited by 46 publications

References 20 publications

Role of Cholecystokinin Receptors in Induction of Antinociception in Hot‐Plate Test

Role of Cholecystokinin Receptors in Induction of Antinociception in Hot‐Plate Test

Antinociceptive Effect of Intracerebroventricular Administration of Cholecystokinin Receptor Agonist and Antagonist in Nerve‐Ligated Mice

The different effects of structurally related sulfakinins on Drosophila melanogaster odor preference and locomotion suggest involvement of distinct mechanisms

Contact Info

Product

Resources

About